 Bone marrow suppression , characterized particularly by thrombocytopenia ( low platelet count ) , may occur during linezolid treatment ; it appears to be the only adverse effect that occurs significantly more frequently with linezolid than with glycopeptides or beta @-@ lactams . It is uncommon in patients who receive the drug for 14 days or fewer , but occurs much more frequently in patients who receive longer courses or who have renal failure . A 2004 case report suggested that pyridoxine ( a form of vitamin B6 ) could reverse the anemia and thrombocytopenia caused by linezolid , but a later , larger study found no protective effect . 
